Table 2.
STUDY | Methods | Outcome Categories | ||||||
---|---|---|---|---|---|---|---|---|
Author | Year | Elicitation Method | Quality of Life | Transient Short Term Side Effects | Severe and Persistent Side Effects | Treatment Response | Progression- and Disease-Free Survival | Overall Survival |
Curative Setting Studies | ||||||||
Pieterse [25] | 2007 | CA | 5 | 4 | 3 | |||
Thrumurthy [27] | 2011 | DCE | 5 | 3 | 4 | 2 | ||
Mohamed [26] | 2011 | DCE | 3 | 4 | 5 | |||
* Jorgensen [28] | 2013 | Rating scale | 3 | 2 | 2 | 5 | 4 | |
Molinari [29] | 2014 | Trade-off | 2 | 5 | 4 | 3 | ||
Thill [16] | 2016 | AHP | 2 | 3 | 5 | 4 | ||
Bröckelmann [46] | 2019 | DCE | 2 | 4 | 5 | 3 | ||
van der Valk [30] | 2020 | CA | 4 | 5 | 3 | 3 | ||
Khan [51] | 2020 | DCE | 5 | 3 | 4 | |||
Werner [31] | 2021 | Rating scale | 4 | 2 | 1 | 3 | 3 | 5 |
Palliative Setting Studies | ||||||||
Havrilesky [33] | 2014 | DCE | 4 | 3 | 2 | 5 | ||
DaCosta [34] | 2014 | CA | 3 | 2 | 4 | 5 | ||
Park [32] | 2012 | DCE | 5 | 4 | 3 | |||
Muhlbacher [35] | 2015 | DCE | 3 | 2 | 5 | 5 | ||
* Uemura [36] | 2016 | DCE | 4 | 1 | 5 | 2 | 3 | |
* Chau [37] | 2016 | Rating scale | 4 | 1 | 5 | 3 | 2 | |
Gonzalez [38] | 2017 | DCE | 3 | 5 | 4 | |||
Liu [39] | 2019 | DCE | 4 | 3 | 2 | 5 | ||
Bröckelmann [46] | 2019 | DCE | 2 | 3 | 5 | 4 | ||
Wong [40] | 2020 | DCE | 4 | 5 | 3 | |||
Khan [50] | 2020 | DCE | 4 | 3 | 5 | |||
* Stegmann [41] | 2020 | OPT | 5 | 3 | 4 | |||
Weilandt [42] | 2021 | DCE | 3 | 2 | 4 | 1 | 5 | |
Both Settings Studies | ||||||||
Johnson [43] | 2006 | CA | 5 | 3 | 4 | |||
Schmidt [44] | 2017 | DCE | 4 | 3 | 5 | |||
Sun [45] | 2019 | DCE | 2 | 3 | 4 | 5 | ||
* Festen [47] | 2019 | OPT | 5 | 3 | 4 | |||
Fifer [49] | 2020 | DCE | 3 | 3 | 4 | 5 | ||
Valenti [48] | 2020 | CA | 4 | 3 | 3 | 5 | ||
* Festen [50] | 2021 | OPT | 5 | 3 | 4 |
Higher numbers represent higher priority (range 0–5). Where an outcome category is not assessed, no number appears. CA = conjoint analysis, DCE = discrete choice experiment, AHP = Analytic hierarchy process, OPT = outcome prioritization tool. * Studies with median age above 70 or separate data for this subgroup.